Yi Yu

Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092

Yi Yu, Ronald E. Savage, Sudharshan Eathiraj et al. · PLoS ONE · 2015 · 121 citations · Full text

Medicine, Oncology, Pharmacology +14

In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS)

Carlotta Ranieri, Silvia Di Tommaso, Daria Carmela Loconte et al. · Neurogenetics · 2018 · 83 citations · Full text

Medicine, Molecular Medicine, Oncology +15

Aberrant Splicing of Cyclin-Dependent Kinase–Associated Protein Phosphatase KAP Increases Proliferation and Migration in Glioblastoma

Yi Yu, Xiuli Jiang, Bradley S. Schoch et al. · Cancer Research · 2007 · 69 citations

Life Sciences, Cancer Biology, Oncology +17

A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity

Eleftherios Kostaras, Teresa Kaserer, Glorianne Lazaro et al. · British Journal of Cancer · 2020 · 37 citations · Full text

Medicine, Oncology, Pharmacology +13

ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease

Kyungho Kim, Jing Li, Andrew Barazia et al. · Haematologica · 2016 · 29 citations · Full text

Medicine, Hematology, Molecular Medicine +17